Ignite Creation Date:
2024-05-06 @ 6:03 PM
Last Modification Date:
2024-10-26 @ 2:40 PM
Study NCT ID:
NCT05528458
Status:
RECRUITING
Last Update Posted:
2024-04-23
First Post:
2022-08-30
Brief Title:
Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
Sponsor:
Samsung Medical Center
Organization:
Samsung Medical Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Lung Adenocarcinoma |
Keywords: